Loading...
Cresco Labs Inc.
CRLBF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$0.68
$0.05(8.03%)
Cresco Labs Inc. (CRLBF) Financial Performance & Income Statement Overview
Review Cresco Labs Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-6.04%
↓ 6.04%
Operating Income Growth
222.17%
↑ 222.17%
Net Income Growth
57.59%
↑ 57.59%
Operating Cash Flow Growth
126.21%
↑ 126.21%
Operating Margin
12.99%
↑ 12.99%
Gross Margin
48.34%
↑ 48.34%
Net Profit Margin
-11.86%
↓ 11.86%
ROE
-17.60%
↓ 17.60%
ROIC
7.27%
↑ 7.27%
Cresco Labs Inc. (CRLBF) Income Statement & Financial Overview
Review Cresco Labs Inc.'s (CRLBF) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $175.91M | $179.78M | $181.18M | $183.47M |
| Cost of Revenue | $91.88M | $86.34M | $94.75M | $97.07M |
| Gross Profit | $84.03M | $93.44M | $86.43M | $86.40M |
| Gross Profit Ratio | $0.48 | $0.52 | $0.48 | $0.47 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $42.05M | $64.78M | $53.51M | $54.79M |
| Operating Expenses | $64.62M | $67.09M | $62.40M | $57.37M |
| Total Costs & Expenses | $156.50M | $153.44M | $148.80M | $154.44M |
| Interest Income | $657000.00 | $771000.00 | $746000.00 | $748000.00 |
| Interest Expense | $13.74M | $15.79M | $14.56M | $14.82M |
| Depreciation & Amortization | $15.64M | $16.62M | $16.44M | $17.22M |
| EBITDA | $31.62M | $43.73M | -$9.94M | $47.85M |
| EBITDA Ratio | $0.18 | $0.24 | -$0.05 | $0.26 |
| Operating Income | $19.41M | $26.34M | $32.38M | $29.03M |
| Operating Income Ratio | $0.11 | $0.15 | $0.18 | $0.16 |
| Other Income/Expenses (Net) | -$16.35M | -$15.02M | -$73.32M | -$13.21M |
| Income Before Tax | $3.06M | $11.32M | -$40.94M | $15.88M |
| Income Before Tax Ratio | $0.02 | $0.06 | -$0.23 | $0.09 |
| Income Tax Expense | $2.62M | $19.02M | $10.24M | $17.92M |
| Net Income | -$4.37M | -$10.54M | -$54.33M | -$5.17M |
| Net Income Ratio | -$0.02 | -$0.06 | -$0.30 | -$0.03 |
| EPS | -$0.01 | -$0.03 | -$0.16 | -$0.02 |
| Diluted EPS | -$0.01 | -$0.03 | -$0.16 | -$0.02 |
| Weighted Avg Shares Outstanding | $349.10M | $347.36M | $344.93M | $341.63M |
| Weighted Avg Shares Outstanding (Diluted) | $349.10M | $347.36M | $344.93M | $341.63M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan